Patents by Inventor R. Glenn Hammonds

R. Glenn Hammonds has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6599717
    Abstract: Vascular Endothelial Growth Factor Receptor (dmVEGFR) nucleic acids and proteins that have been isolated from Drosophila melanogaster are described. The dmVEGFR nucleic acids and proteins can be used to genetically modify metazoan invertebrate organisms, such as insects and worms, or cultured cells, resulting in dmVEGPR expression or mis-expression. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds which are potential therapeutics that interact with dmVEGFR protein. They can also be used in methods for studying dmVEGFR activity and identifying other genes that modulate the function of, or interact with, the dmVEGFR gene.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: July 29, 2003
    Assignee: Exelixis, Inc.
    Inventors: Allen James Ebens, Jr., R. Glenn Hammonds, Jonathan C. Heller, Greg Weddell, John W. Winslow
  • Patent number: 6255068
    Abstract: An activator of the Rse receptor protein tyrosine kinase has been identified which is encoded by growth arrest-specific gene 6 (gas6). Accordingly, the present invention provides variant gas6 polypeptides, compositions comprising variant gas6 polypeptides, nucleic acids encoding variant gas6 polypeptides, vectors comprising those nucleic acids and host cells comprising those vectors. The present invention is further directed to methods for making variant gas6 polypeptides.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: July 3, 2001
    Assignee: Genentech, Inc.
    Inventors: Paul J. Godowski, R. Glenn Hammonds, Melanie R. Mark
  • Patent number: 6211142
    Abstract: An activator of the Rse receptor protein tyrosine kinase has been identified which is encoded by growth arrest-specific gene 6 (gas6). Accordingly, the present invention provides compositions comprising gas6 polypeptides wherein the gas6 polypeptides are present in an amount effective for activating the Rse receptor. The present invention is further directed to articles of manufacture comprising gas6 polypeptides such as kits and containers containing gas6 polypeptide compositions and gas6 polypeptide In a liposome or adsorbed to a membrane.
    Type: Grant
    Filed: March 10, 1995
    Date of Patent: April 3, 2001
    Assignee: Genentech, Inc.
    Inventors: R. Glenn Hammonds, Paul J. Godowski, Melanie R. Mark
  • Patent number: 6169070
    Abstract: The translation product of the growth arrest-specific gene 6 (gas6) has been identified as an activator of the Mer receptor protein tyrosine kinase. The invention accordingly provides methods of activating Mer receptor in cells expressing it by exposing them to exogenous gas6 polypeptides. Also provided are methods of enhancing the growth, differentiation, or survival of such cells using gas6 polypeptides.
    Type: Grant
    Filed: April 17, 1996
    Date of Patent: January 2, 2001
    Assignee: Genentech, Inc.
    Inventors: Jian Chen, R. Glenn Hammonds, Paul J. Godowski, Melanie R. Mark, Jennie P. Mather, Ronghao Li
  • Patent number: 5955420
    Abstract: An activator of the Rse receptor protein tyrosine kinase has been identified which is encoded by growth arrest-specific gene 6 (gas6). Accordingly, the present invention provides a method of activating the Rse receptor by exposing a cell comprising the Rse receptor to exogenous gas6 polypeptide. Moreover, the present invention is directed to a method for enhancing the survival, proliferation or differentiation of a cell comprising a Rse receptor by exposing the cell to exogenous gas6 polypeptide. The types of cells which can be treated according to the method include glial cells such as Schwann cells.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: September 21, 1999
    Assignee: Genentech, Inc.
    Inventors: Jian Chen, R. Glenn Hammonds, Paul J. Godowski, Melanie R. Mark, Jennie P. Mather, Ronghao Li
  • Patent number: 5688760
    Abstract: Polypeptides comprising an N-terminal amino acid sequence corresponding to amino acids 107-111 of parathyroid hormone related protein (PTHrP) having bone resorption inhibitory activity are provided. The polypeptides are provided in pharmaceutical compositions for the treatment of diseases and disorders where inhibition of bone resorption is indicated.
    Type: Grant
    Filed: August 12, 1993
    Date of Patent: November 18, 1997
    Assignees: Genentech, Inc., The University of Melbourne
    Inventors: Bruce E. Kemp, Geoffrey C. Nicholson, Thomas J. Martin, Anna J. Fenton, R. Glenn Hammonds
  • Patent number: 5688763
    Abstract: Growth hormone receptor and growth hormone binding protein are purified enabling amino acid sequence and DNA isolates coding for growth hormone receptor and growth hormone binding protein and methods of obtaining such DNA are provided, together with expression systems for recombinant production of growth hormone receptor and growth hormone binding protein. Therapeutically useful forms of the growth hormone receptor and growth hormone binding protein and anti-receptor antibodies are described.
    Type: Grant
    Filed: May 25, 1994
    Date of Patent: November 18, 1997
    Inventors: R. Glenn Hammonds, Jr., David W. Leung, Steven A. Spencer, William I. Wood, Peter Cameron Colosi
  • Patent number: 5168050
    Abstract: A DNA construct is provided comprising DNA encoding a mature BMP-2 upstream of which is DNA encoding a precursor portion of a mammalian protein other than the BMP-2. Also provided are mammalian expression vectors and hosts containing such a DNA construct and methods for improved expression using such construct.
    Type: Grant
    Filed: May 24, 1990
    Date of Patent: December 1, 1992
    Assignee: Genentech, Inc.
    Inventors: R. Glenn Hammonds, Jr., Anthony J. Mason
  • Patent number: 5057417
    Abstract: Growth hormone receptor and growth hormone binding protein are purified enabling amino acid sequence and DNA isolates coding for growth hormone receptor and growth hormone binding protein and methods of obtaining such DNA are provided, together with expression systems for recombinant production of growth hormone receptor and growth hormone binding protein. Therapeutically useful forms of the growth hormone receptor and growth hormone binding protein and anti-receptor antibodies are described.
    Type: Grant
    Filed: June 12, 1987
    Date of Patent: October 15, 1991
    Assignee: Genentech, Inc.
    Inventors: R. Glenn Hammonds, David W. Leung, Steven A. Spencer, William I. Wood
  • Patent number: 4857637
    Abstract: The activity of growth-associated receptors is modulated in vivo in a controlled and reproducible fashion by immunizing animals against target growth-associated receptors. This is accomplished by the use of immunogens predetermined to induce primarily agonist or antagonist responses. The immunogens include anti-ligand antibodies and receptor derivatives.
    Type: Grant
    Filed: June 12, 1987
    Date of Patent: August 15, 1989
    Assignee: Genentech, Inc.
    Inventors: R. Glenn Hammonds, David W. Leung, David W. Martin, Jr., Steven A. Spencer, William I. Wood
  • Patent number: 4624944
    Abstract: The present invention discloses novel gonadal peptides with inhibin-like activity. The novel peptides include two gonadal peptides, one consisting of 52 amino acids, the other consisting of 92 amino acids. Both of these peptides were initially isolated from human seminal plasma. Both have now been chemically synthesized. The novel peptides are designated as alpha-inhibin-52 and alpha-inhibin-92. Sequence analyses show that the NH.sub.2 -terminal 31 amino acids of alpha-inhibin-52 are identical to the structure of the 31 amino acid inhibin-like peptide previously reported by Ramasharma, et al. (1984). Sequence analyses also show that the COOH-terminal 52 amino acids of alpha-inhibin-92 are identical to the structure of alpha-inhibin-52. The amino acid sequence of alpha-inhibin-92 is: ##STR1## .
    Type: Grant
    Filed: June 14, 1985
    Date of Patent: November 25, 1986
    Assignee: The Regents of The University of California
    Inventors: Choh H. Li, David Chung, R. Glenn Hammonds, Jr., Kristipati Ramasharma